Skip to main content

Table 5 Mean change in central pulse pressure (mmHg) after EMPA therapy separated according to median of different variables

From: How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

Variable

Age

HbA1c

Copeptin

Heart rate

LDL-cholesterol

Uric acid

Systolic BP

hsCRP

≥ median

− 4.66 ± 8.87

− 4.77 ± 9.04

− 5.54 ± 8.25

− 1.03 ± 9.37

− 1.95 ± 11.9

− 3.978 ± 9.39

− 2.65 ± 9.46

− 1.82 ± 8.11

< median

− 0.83 ± 9.27

− 0.84 ± 9.08

− 0.47 ± 9.43

− 4.45 ± 8.86

− 3.48 ± 5.82

− 1.51 ± 8.99

− 2.81 ± 9.13

− 3.67 ± 10.2

p-value

0.114

0.105

0.033

0.160

0.533

0.311

0.949

0.449

  1. Data are given as mean ± SD
  2. hsCRP high sensitive C-reactive protein, LDL-cholesterol low density lipid cholesterol, heart rate 24-h ambulatory heart rate, systolic BP systolic 24-h ambulatory blood pressure